Join the movement
We can change the trajectory of colorectal cancer together.
We can change the trajectory of colorectal cancer together.

Project Cure CRC is a multi-faceted effort combining innovative research and cutting-edge venture philanthropy. Ending colorectal cancer will take all of us, in collaboration, driving urgently toward cures.
Project Cure CRC’s fund for breakthoughs supports science from a wide variety of researchers.
Supports early-career faculty with innovative ideas in CRC research, providing up to $200,000 over two years for original preclinical, translational, or early clinical projects.
Funds transformative research to advance CRC therapies, offering up to $500,000 over two years for senior investigators proposing localized or metastatic CRC projects.
Encourages high-risk, high-reward CRC research with clear hypotheses, providing up to $200,000 over two years to establish proof-of-concept.
Supports collaborative, multidisciplinary CRC research teams with up to $500,000 over two years to drive curative science and innovation.
The Opportunistic Award is not being offered as of October 1, 2025. Funding opportunities for small biotech companies are being included in a Request for Proposals for K-SPY, Project Cure CRC’s adaptive clinical trial platform with release anticipated by mid-November 2025. The Alliance encourages small companies focused on new therapies and technologies for colorectal cancer to review the forthcoming RFP and submit proposals to accelerate new cures for CRC patients.
Project Cure CRC prioritizes high-risk/high-reward proposals that fast-track research toward curative solutions, with a strong preference for collaborative and public-private partnerships.

Project Cure CRC, a $100 million initiative by the Colorectal Cancer Alliance (Alliance), continues to revolutionize colorectal cancer research by announcing three new groundbreaking grants aimed at transforming patient care.

The Alliance's Project Cure CRC announces $1.3 million in new research grants — bringing total funding to nearly $12 million — to drive breakthroughs in colorectal cancer care and address critical research gaps.

The 2025 ASCO Annual Meeting featured several important studies that could change how colorectal cancer is treated, including a pivotal study for BRAF V600E patients.